▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Xconomy .com

xconomycom

Recent Articles by Xconomy .com

Apr 6, 2017 by Xconomy .com

Beyond the Tablet Wars: Apple, Amazon, and the Cloud

What makes them both great will keep them great for years to come.

Apr 6, 2017 by Xconomy .com

AT&T Drops T-Mobile Bid, Will Pay $4B Breakup Fee

But what about the spectrum deal?

Apr 6, 2017 by Xconomy .com

Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs

What does this important collaboration mean for biosimilars?

Apr 6, 2017 by Xconomy .com

What Now? Reactions, Questions After the AT&T-Mo Failure

Are T-Mobile and Sprint the next hottest couple in wireless?

Nov 7, 2016 by Xconomy .com

Vertex Names Jeff Leiden as New CEO, Staring Down Tough Competition

What does new leadership mean for Vertex's future?

Nov 7, 2016 by Xconomy .com

Zillow Shows Why Microsoft Might Love the Kindle Fire: No Google Maps

No Google Maps!

Apr 6, 2017 by Xconomy .com

Affymax Passes FDA Panel Scrutiny, Looks to Challenge Amgen Anemia Drug

Many investors wrote off Affymax in June 2010, but was that premature?

Nov 7, 2016 by Xconomy .com

Pfizer Acquires Excaliard, an Isis Spinout With Drug to Fight Excessive Scarring

Pfizer is making a new bet on a new drug to fight excessive scarring.

Apr 6, 2017 by Xconomy .com

Regeneron Wins FDA Approval for Macular-Degeneration Drug

The company can begin selling Eylea, which treats the leading cause of blindness in the elderly.

Nov 7, 2016 by Xconomy .com

Amazon Pushing National Sales-Tax Bill

Looks like Amazon.com's pugnacious bet on national sales tax reform is paying off.

Nov 7, 2016 by Xconomy .com

Celgene To Pump $45M into Quanticel to Discover Cancer Drugs, Gets Option To Acquire

Celgene strikes an unusual agreement.

Nov 7, 2016 by Xconomy .com

Agios and Celgene: Anatomy of an Ultra-Valuable Biotech Marriage

An unprecedented cancer drug development deal.

Apr 6, 2017 by Xconomy .com

Sprint Makes It Pretty Clear: Clearwire's on Its Own

Shares plummet as Sprint unveils plans that don't include the WiMax provider.

Apr 6, 2017 by Xconomy .com

How Steve Jobs Rewired Our Lives -- and Raised Our Expectations

Steve Jobs' real legacy.

Nov 7, 2016 by Xconomy .com

Merck Fine-Tunes Biosimilars Strategy as FDA Guidelines Loom

Merck readies itself to enter this potential new market.

Nov 7, 2016 by Xconomy .com

Why Amazon’s Tablet Matters: It’s Not a Computer. It’s a Store.

Is this the iPad killer after all?

Apr 6, 2017 by Xconomy .com

What the Changes at Facebook Mean for Apple and Google -- and You

Turning the social network inside out.

Apr 6, 2017 by Xconomy .com

Orexigen Revives Obesity Drug After One More Go-Round With FDA

Orexigen has new life.

Apr 6, 2017 by Xconomy .com

Bristol-Pfizer Team on Alert as FDA Reviews Stroke-Prevention Drug From Rivals J&J and Bayer

Who will come out ahead?

Apr 6, 2017 by Xconomy .com

Steve Jobs Calling: The Stuff of Customer Service Legend

What kind of company will Apple be without Jobs?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services